

## Thrombotargets Corp

*Cardiovascular Disease, High Throughput Screening, Drug Discovery*

**2530 Meridian  
Parkway, Suite 3023  
Durham, North  
Carolina 27713  
USA**

Incorporated in 2005  
10 Employees

**Privately Held**

**<http://www.thrombotargets.com>**

Phone: 1 (919) 8064322

Fax: 1 (919) 8064301

### Delegates

Luis Caveda                      Chief Operating Officer

### Highlights

#### Recent

FDA had granted TT-103MH with Orphan Drug Designation for the treatment of cutaneous injury and bleeding occurs during dental procedures in hemophiliac patients. IND submission in Q4-2007 Preclinica Phase of TT-105 a novel anticoagulant drug.

Contract signed with Asinex, Moscow, Rusia and Specs, Delft, Holland for screening small molecules libraries with our own HTS System, BioplatfromScreen. The succes of this colaboration was the discovery of two new potent antifibrinolytic drug candidate.

Closed seed financing round and Round A (Public Founds: 1.2 MUSD and Venture Capital: 4.9 MUSD)

#### Anticipated

Fall 2007 we expect to raise venture founds and to close Round B of Financing for 30 MUSD.

Clinical Phase I of TT-103MH for topic treatment of bleeding disorders and Clinical Phase I of TT-105 a new anticoagulant drug. Co-development agreements with Big Pharma.

Creation of a Big HTS Laboratory. New leads from agreements with library suppliers. Agreements with Big Pharma in the area of HTS. Reach a Licencing agreement for TT-103MH.

### Corporate Mission

Thrombotargets is an innovative drug discovery and development group of biotech companies developing new medicines based on advances in recombinant DNA and small molecule drug technologies. Thrombotargets' s programs leverage the company's haemostasis expertise and are focused on inherited and acquired Hemorrhagic and Thrombotic disorders.

Thrombotargets group is comprised by three companies; Thrombotargets Corporation (Durham, NC, USA.) is responsible for Drug Development and Business Management; Thrombotargets Europe (Barcelona, Spain) for Target Identification, Lead Validation, Lead Optimization and High Throughput Screening and Biotech Libraries (Girona, Spain) for engineered targeted libraries.

Thrombotargets' s strategy is to build stockholder value by discovering new leads and advancing them to clinical phases

With a primary focus on therapeutics for Haemostasis and Thrombotic diseases, Thrombotargets' s objective is to identify, optimize and develop highly efficacious biotech and small molecule leads with low risk profiles and large market opportunities.

Thrombotargets will achieve their objectives by operating a balanced risk business strategy:

1. Invest in our own discovery and development programs and drive these through to clinical phases before partnering the candidate with pharmaceutical companies. Thrombotargets will be compensated for this innovation and effort primarily through license fees, milestones and royalties on drug sales.
2. Collaborate with the pharmaceutical industry leaders to share the investment and the rewards associated with generating market outcomes for innovative new therapies.
3. Through the in-licensing of programs at stages of development that complement and balance our existing internal portfolio, Thombotargets leverage external innovation

### Proprietary Technology

Thrombotargets has developed and adapted to High Throughput Screening (HTS), a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary HTS Platforms named BioPlatformScreen™, the Thrombotargets group is creating a continuously novel and promising pipeline. Presently, two of Thrombotargets most innovative drug candidates, TH-103MH, a novel antihemorrhagic human recombinant protein to be use topically, and TT-105, a novel anticoagulant monoclonal antibody, are undergoing Preclinical trials; these programs will begin Phase I clinical trials Q4, 2007. Recently we begun a new antifibrinolytic program

(TT-111 and TT-112) in collaboration with ASINEX, Rusia due to results in the exploitation of our BioplatformScreen Technology.

## Current Alliances

Asinex, Moscow, Rusia  
 Specs, Delft, Netherland  
 Villapharma, Murcia, Spain  
 Lipso, Girona, Spain  
 IUCT, Barcelona, Spain

## Intellectual Property Status

Thrombotargets patents state protect our intellectual property and permit the commercialization of our technologies and compounds.

## Products

<u>Name</u>	<u>Indication</u>	<u>Phase</u>	<u>Milestone</u>
TT-103MH	Topic use of bleeding disorders	Preclinical	Phase 2
TT-105	Anticoagulant	Preclinical	Phase 1
TT-111	Antifibrinolytic	Drug Discovery	Phase 1
TT-112	Antifibrinolytic	Drug Discovery	Phase 1
TT-113	Antiplatelet	Drug Discovery	Phase 1
TT-116	Fibrinolytic	Drug Discovery	Phase 1

## Financing Strategy

<i>Most Recent Completed Round</i>	A Round
<i>Total Amount Raised to Date (All Rounds)</i>	6.02 M USD
<i>Seed Round</i>	\$1.12 million Euro (August 2005)
<i>A Round</i>	\$4.9 million Euro (December 2007)

## Investors

<u>Name</u>	<u>Stake</u>
Javier Pedreno	29.3
Luis Caveda	10
Nayade World S.L.	21.3
Dager S.L.	21.3
Biotech Angels S.L.	18



### Senior Management

Name                      Title

Javier Pedreno              Chief Executive Officer

Luis Caveda                  COO

Luis Aced                      CFO

Lina Badimon                Associated Scientific Consultant

Juan Ramon Rodriguez    CSO

### Board of Directors

Name                      Title                      Affiliation

Javier Pedreno              President                      Reus University, Spain

Luis Caveda                  Chief Operating Officer COO

Juan Ramon Rodriguez    R&D Director              National Biotechnology Center, Madrid, Spain

Rosa Fernandez            Project Development Director              Pre Natal Care Program for Catalonia Region, Spain

Luis Aced                      CFO                              Aced Acesores

Ignasi Miquel                Strategic Aliances Director

### Scientific Advisory Board

Name                      Title                      Affiliation

Ruben Zamora              Assistant Profesor              University of Pittsburg, PA, USA

Francisco Gonzalez        Professor                      Biotechnology National Center, Madrid, Spain

Elisabetta Dejana            Head Vascular Biology Department              IFOM, Milan, Italy